DK1086093T3 - Tetrahydroquinolinderivater som glycinantagonister - Google Patents

Tetrahydroquinolinderivater som glycinantagonister

Info

Publication number
DK1086093T3
DK1086093T3 DK99927911T DK99927911T DK1086093T3 DK 1086093 T3 DK1086093 T3 DK 1086093T3 DK 99927911 T DK99927911 T DK 99927911T DK 99927911 T DK99927911 T DK 99927911T DK 1086093 T3 DK1086093 T3 DK 1086093T3
Authority
DK
Denmark
Prior art keywords
tetrahydroquinoline derivatives
glycine antagonists
antagonists
glycine
tetrahydroquinoline
Prior art date
Application number
DK99927911T
Other languages
Danish (da)
English (en)
Inventor
Fabio Romano Di
Original Assignee
Glaxosmithkline Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812408.4A external-priority patent/GB9812408D0/en
Priority claimed from GBGB9812410.0A external-priority patent/GB9812410D0/en
Application filed by Glaxosmithkline Spa filed Critical Glaxosmithkline Spa
Application granted granted Critical
Publication of DK1086093T3 publication Critical patent/DK1086093T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK99927911T 1998-06-10 1999-06-08 Tetrahydroquinolinderivater som glycinantagonister DK1086093T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812408.4A GB9812408D0 (en) 1998-06-10 1998-06-10 Heterocyclic compounds
GBGB9812410.0A GB9812410D0 (en) 1998-06-10 1998-06-10 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
DK1086093T3 true DK1086093T3 (da) 2005-11-28

Family

ID=26313826

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99927911T DK1086093T3 (da) 1998-06-10 1999-06-08 Tetrahydroquinolinderivater som glycinantagonister

Country Status (34)

Country Link
US (3) US6362199B1 (is)
EP (1) EP1086093B1 (is)
JP (1) JP2002517492A (is)
KR (1) KR100586762B1 (is)
CN (1) CN1173970C (is)
AP (1) AP2000002008A0 (is)
AR (1) AR018632A1 (is)
AT (1) ATE301650T1 (is)
AU (1) AU753867B2 (is)
BG (1) BG105123A (is)
BR (1) BR9911145A (is)
CA (1) CA2334727C (is)
CO (1) CO5080785A1 (is)
CZ (1) CZ293605B6 (is)
DE (1) DE69926632T2 (is)
DK (1) DK1086093T3 (is)
EA (1) EA003276B1 (is)
EE (1) EE200000733A (is)
ES (1) ES2249010T3 (is)
HK (1) HK1034079A1 (is)
HR (1) HRP20000845A2 (is)
HU (1) HUP0102767A3 (is)
ID (1) ID27845A (is)
IL (2) IL140062A0 (is)
IS (1) IS5746A (is)
MY (1) MY125037A (is)
NO (1) NO321904B1 (is)
NZ (1) NZ508638A (is)
OA (1) OA11564A (is)
PE (1) PE20000724A1 (is)
PL (1) PL197160B1 (is)
TR (1) TR200003652T2 (is)
TW (1) TWI229079B (is)
WO (1) WO1999064411A1 (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10000311A1 (de) 2000-01-05 2001-07-12 Gruenenthal Gmbh Aminomethyl-Phonyl-Cyclohexanonderivate
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137488A1 (de) * 2001-08-03 2003-02-20 Gruenenthal Gmbh Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137487A1 (de) * 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
WO2006091674A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2024516C1 (ru) * 1989-02-02 1994-12-15 Яманути Фармасьютикал Ко., Лтд. Способ получения производного тетрагидробензимидазола или его фармацевтически приемлемой соли
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
TR199800531T1 (xx) 1995-09-29 1998-06-22 Glaxo Wellcome Spa NMDA antagonistleri olarak tetrahidrokinolinler.
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
NZ508638A (en) 2003-08-29
JP2002517492A (ja) 2002-06-18
KR20010052722A (ko) 2001-06-25
CA2334727A1 (en) 1999-12-16
ES2249010T3 (es) 2006-03-16
CO5080785A1 (es) 2001-09-25
CZ293605B6 (cs) 2004-06-16
HK1034079A1 (en) 2001-10-12
PL344694A1 (en) 2001-11-19
CN1311785A (zh) 2001-09-05
HUP0102767A3 (en) 2003-01-28
US6362199B1 (en) 2002-03-26
AP2000002008A0 (en) 2000-12-31
US20020052391A1 (en) 2002-05-02
IL140062A0 (en) 2002-02-10
CA2334727C (en) 2009-08-04
PE20000724A1 (es) 2000-08-17
NO20006227L (no) 2001-02-08
AU753867B2 (en) 2002-10-31
OA11564A (en) 2004-05-24
AR018632A1 (es) 2001-11-28
TR200003652T2 (tr) 2001-04-20
EP1086093B1 (en) 2005-08-10
NO20006227D0 (no) 2000-12-07
EA200001165A1 (ru) 2001-06-25
EP1086093A1 (en) 2001-03-28
DE69926632D1 (de) 2005-09-15
BR9911145A (pt) 2001-03-06
PL197160B1 (pl) 2008-03-31
IL140062A (en) 2007-05-15
TWI229079B (en) 2005-03-11
MY125037A (en) 2006-07-31
EE200000733A (et) 2002-06-17
CN1173970C (zh) 2004-11-03
HUP0102767A2 (hu) 2001-12-28
BG105123A (en) 2001-11-30
IS5746A (is) 2000-11-30
NO321904B1 (no) 2006-07-17
KR100586762B1 (ko) 2006-06-08
CZ20004587A3 (en) 2001-05-16
US20020169186A1 (en) 2002-11-14
EA003276B1 (ru) 2003-04-24
DE69926632T2 (de) 2006-01-19
HRP20000845A2 (en) 2001-10-31
US6495566B2 (en) 2002-12-17
ATE301650T1 (de) 2005-08-15
US6413985B1 (en) 2002-07-02
ID27845A (id) 2001-04-26
AU4509299A (en) 1999-12-30
WO1999064411A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
NO20013003D0 (no) Kinolin-derivater
DK1073639T3 (da) Chinolinderivater
ATE250036T1 (de) Chinolinderivate
ATE240327T1 (de) 1,2-annelierte chinolinderivate
NO20010193D0 (no) Tiobenzimidazol-derivater
ATE236136T1 (de) Benzosulfonderivate
ATE229005T1 (de) Chinolinderivate
ATE259810T1 (de) Phenyl-xanthinderivate
NO20010514D0 (no) Aminometylkarboksylsyre-derivater
DK0922034T3 (da) Tetrahydroquinolinderivater som EAA-antagonister
EE200000428A (et) VLA-4 antagonistid
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
DK1086093T3 (da) Tetrahydroquinolinderivater som glycinantagonister
NO20011512L (no) 2-Fenylpyran-4-on derivater
ATE233253T1 (de) Chromanderivate
DK1060183T3 (da) 5-deoxycytidinderivater
NO996244D0 (no) Pyrrolidinkarboksylsyrederivater som endotelinantagonister
NO20002575D0 (no) Substituerte oksimer som neurokininantagonister
FI980053A0 (fi) Anordning foer utformande av fiberbollar av laongstraeckta fibrer som foeljer med enluftstroem
FI970143A0 (fi) Kinoliinijohdannaiset leukotrieeniantagonisteina
SI1086093T1 (sl) Derivati tetrahidrokinolina kot antagonisti glicina
FI980755A0 (fi) Foerfarande foer montering/faestande av vaermeisoleringsskivor som vaermeisolering i en byggnad
FI980722A0 (fi) Motions-, rehabiliterings-, sport- och lagspelredskap som staerker baolens muskler